CCIA
IMNM icon

Campbell & Co Investment Adviser’s Immunome IMNM Stock Holding History

Campbell & Co Investment Adviser’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$394K Buy
+18,013
New +$401K 0.02% 806

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Campbell & Co Investment Adviser's IMNM Position: Q1 2026 in Review

Campbell & Co Investment Adviser opened a new position in Immunome (IMNM) in Q1 2026: 18,013 shares worth $394K. The stake represents 0.02% of the portfolio and ranks #806 among its holdings.

200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Campbell & Co Investment Adviser held 18,013 shares of Immunome worth $394K as of Q1 2026.
  • Immunome was a new Campbell & Co Investment Adviser position in Q1 2026.
  • Immunome made up 0.02% of Campbell & Co Investment Adviser's portfolio in Q1 2026, its #806 holding.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.